Celularity (CELU) to Release Earnings on Thursday

Celularity (NASDAQ:CELU) is expected to release its Q4 2025 resultson Thursday, March 26th. Analysts expect Celularity to post earnings of ($1.50) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Celularity Stock Performance

Shares of CELU opened at $1.21 on Tuesday. The firm has a market cap of $34.90 million, a PE ratio of -0.36 and a beta of 0.79. Celularity has a 52-week low of $1.01 and a 52-week high of $4.35. The business’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.63.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CELU. XTX Topco Ltd acquired a new stake in Celularity in the fourth quarter worth $33,000. Acadian Asset Management LLC acquired a new position in shares of Celularity during the first quarter valued at about $34,000. Jane Street Group LLC acquired a new position in shares of Celularity during the fourth quarter valued at about $46,000. Bank of America Corp DE boosted its position in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after purchasing an additional 35,023 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Celularity by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after purchasing an additional 20,876 shares in the last quarter. Institutional investors and hedge funds own 19.02% of the company’s stock.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.